As medical weight loss continues to evolve in 2026, the landscape of GLP-1 therapies has reached a pivotal moment with ...

Waymo is rapidly expanding, processing over 450,000 paid rides per week, and is reportedly in talks to raise over $15 billion ...

Pfizer ( PFE +0.24%) pays a dividend that yields around 6.8%. While the yield has been pushed higher as share prices have ...

Older adults with type 2 diabetes who started taking certain newer medications—such as empagliflozin (Jardiance), dapagliflozin (Farxiga), semaglutide (Ozempic), or liraglutide (Victoza)—were less ...

CMS released plans Dec. 23 for its voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” — or BALANCE — model. The announcement comes weeks following the White House’s ...

As GLP-1 weight-loss drugs become more common, their effects may be reshaping everyday food choices in ways that extend far ...

On December 22, 2025, the U.S. Food and Drug Administration (FDA) formally approved Wegovy® pills, marking a major milestone in obesity treatment. The new medication from Novo Nordisk is designed as a ...

Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes ...

Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management ...

Food makers and restaurants adjust menus and products as GLP-1 drugs drive demand for high-protein foods and smaller portions ...

Fewer people in the U.S. are drinking alcohol these days. The holidays have long been a season to overindulge, whether that means too many glasses of wine or too many cookies. But this year may be ...

Novo Nordisk's Wegovy pill is the first oral GLP-1 receptor agonist approved for weight management, offering a new treatment ...